CS2009是一款同时靶向PD-1、CTLA-4和VEGFA的药物，具有潜在同类首创的作用机理。 CS2009拥有平衡的抗PD-1和抗CTLA-4亲和力，可以同时结合PD-1、CTLA-4及VEGFA三个靶点。

We wanted to create a monitoring tool that helps clinicians understand what is going on in the patient at a precise level, ...

During a Case-Based Roundtable® event, Patrick M. Forde, MD, discussed safety and tolerability concerns with immunotherapy in ...

PD-1 and PD-L1 immune checkpoint inhibitors (ICIs) for treating advanced cancer were associated with an increased risk of new ...

CStone Pharmaceuticals (HK:2616) has released an update. CStone Pharmaceuticals has unveiled promising preclinical data for ...

公司以海报形式介绍其抗 CTLA-4 SAFEbody®ADG126（Muzastotug）作为单一疗法和与抗 PD-1 疗法联合治疗的最新临床数据，进一步验证其显著提高了治疗指数 ...

Macrogenics is positioned at the top for Revenue Growth with a decline of 17.81%, while its peer is at the bottom with a decrease of 59.42%. In terms of Gross Profit, Macrogenics is ahead with $7.97M, ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination ...

Adagene (ADAG) announced data at the SITC 39th Annual Meeting, taking place in Houston, Nov. 6 – 10, 2024. The two poster presentations ...